Impaired postprandial fibroblast growth factor (FGF)-19 response in patients with stage 5 chronic kidney diseases is ameliorated following antioxidative therapy

Abstract

In advanced CKD, the postprandial FGF-19 response appears to be blunted, with partial normalization following antioxidative treatments. A blunted FGF-19 response was associated with impaired insulin and C-peptide signalling.

Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases

“…Impaired FGF19 response in mice after feeding was also observed in oxidative stressassociated late-stage chronic kidney disease (104). The study also confirmed that the abnormal plasma FGF19 levels were corrected by antioxidative therapy (104). Conversely, recent studies have revealed that serum FGF21 levels were higher in the patients with both chronic and acute renal dysfunction (105).…”

“…Circulating FGF19 levels are potential predictors of endstage renal disease (103). Impaired FGF19 response in mice after feeding was also observed in oxidative stressassociated late-stage chronic kidney disease (104). The study also confirmed that the abnormal plasma FGF19 levels were corrected by antioxidative therapy (104).…”

Circulating Fibroblast Growth Factor 19 in Portal and Systemic Blood

“…It binds to the receptor fibroblast growth factor receptor 4 (FGFR4) and a co-factor called bKlotho that stabilizes the binding and signals via MAP kinases to inhibit CYP7A1. [7][8][9] Systemic FGF19 concentrations have been described in both fasting and fed state 10,11 but postprandial levels of FGF19 in portal blood still remain unknown. In this clinical study we aimed to characterize fasting and postprandial FGF19 levels in portal and systemic blood to clarify if physiological portal levels of FGF19 can be extrapolated from the concentration of FGF19 in systemic blood.…”

Short-term and Divergent Regulation of FGF-19 and FGF-21 during Oral Lipid Tolerance Test but not Oral Glucose Tolerance Test

“…One study on 153 healthy volunteers and 66 persons with metabolic syndrome found no significant correlations of FGF-19 with metabolic parameters in the healthy controls but reported lower FGF-19 concentrations in those with metabolic syndrome in which FGF-19 was associated with several cardiovascular risk factors [13]. A small study on 6 haemodialysis patients reported on a postprandial increase of FGF-19 levels by using a mixed meal whereas this response was blunted in patients suffering from advanced kidney disease [14]. In a small study on type 2 diabetic patients with metabolic syndrome, FGF-19 levels were low when compared to controls and negatively correlated to several known cardiovascular risk factors [15,16].…”